CDC says no sign yet that swine flu is mutating

Jul 23, 2009 By LAURAN NEERGAARD , AP Medical Writer

(AP) -- Federal health officials say the new swine flu isn't yet mutating to become more dangerous, but they're closely tracking that as the virus continues to circle the globe.

Dr. Nancy Cox of the calls it "quite surprising" that more hasn't emerged given the virus' quick spread - sickening more than an estimated million people in the U.S. alone since April.

People under 25 get sick most often, although most of the 262 deaths recorded in the U.S. so far have been in 25- to 49-year-olds. People older than 65 have far lower risk of getting sick - perhaps because of years of exposure to viruses in the same influenza family.

THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP's earlier story is below.

WASHINGTON (AP) - Attention is shifting to the world's five leading flu vaccine makers: How fast are they really producing swine flu vaccine, and just how do they plan to test that it works?

A meeting Thursday of the Food and Drug Administration's scientific advisers offers the first in-depth public progress report since U.S. scientists delivered the novel virus to manufacturers and asked them to turn it into usable vaccine.

They've succeeded to a degree. The National Institutes of Health on Wednesday called for a few thousand volunteers, from babies to the elderly, for studies to see if pilot batches are safe and protective. The first shots should go into adult volunteers' arms in early August, with child studies to follow quickly if there are no signs of immediate side effects.

Those government-directed studies - and more that manufacturers will run - are key as the government decides whether to offer vaccine to millions of Americans starting in mid-October, besides vaccinating against the regular winter flu. Health authorities in other countries are looking to the U.S. studies, too, as they make their own plans.

Assuming the studies show the vaccine is OK, a big question is how much will be available and when. Last week, the World Health Organization warned that production is going slower than predicted, with the strains now in use yielding only about half as much of the main vaccine ingredient as is usual.

Wednesday, London-based GlaxoSmithKline echoed that caution, saying it is "working as quickly as possible" but being hindered by those low yields.

"Some of us are skeptical that very much will be available by mid-October," said Dr. William Schaffner, a vaccine specialist at Vanderbilt University.

And the government has warned that any vaccination campaign will put higher-risk people in line for the first batches, as supplies gradually increase over time.

Manufacturers' vaccine studies are expected to largely mirror the NIH's plans: Volunteers will get two vaccinations, 21 days apart. By early September, the NIH should have blood tests showing how much immune protection the initial inoculation triggered, and if a low-dose or higher-dose version was needed. It will take another month to get information on the second inoculation.

Complicating the question: If plain vaccine doesn't spur enough protection or there isn't enough supply, manufacturers could add immune-system boosters called adjuvants. That will pose a dilemma as the U.S. has never approved a flu vaccine containing those ingredients, although they are widely used in vaccine given to older adults in Europe.

But there's little information on their safety in children and pregnant women. Dr. Anthony Fauci, the NIH's infectious disease chief, said it's highly unlikely that flu vaccine with an adjuvant would be part of a children's immunization campaign. Part of FDA's debate Thursday, however, is how to do additional testing of that combination in various age groups.

The NIH's first studies will use flu shots made by France-based Sanofi-Pasteur and CSL Ltd., which on Wednesday began a much smaller study of its vaccine in its home country of Australia.

Also yet to be studied are shots made by Glaxo and Swiss-based Novartis, and a nasal-spray from Maryland-based MedImmune.

---

On the Net:

: http://www.fda.gov/

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Senegal monitors contacts of 1st Ebola patient

add to favorites email to friend print save as pdf

Related Stories

Manufacturers brewing new swine flu vaccine

Jul 23, 2009

(AP) -- Attention is shifting to the world's five leading flu vaccine makers: How fast are they really producing swine flu vaccine, and just how do they plan to test that it works?

Govt calls for volunteers to test swine flu shots

Jul 22, 2009

(AP) -- The race is on: The government and vaccine makers are seeking thousands of volunteers, from babies to the elderly, to roll up their sleeves for the first swine flu shots - to test whether a new vaccine really will ...

US wants ingredient in swine flu vaccine by May

Apr 28, 2009

(AP) -- U.S. scientists hope to have a key ingredient for a swine flu vaccine ready in early May, but tell The Associated Press that the novel virus grows slowly in eggs - the chief way flu vaccines are made.

CDC says October soonest for swine flu shots

May 28, 2009

(AP) -- A U.S. health official said a swine flu vaccine could be available as early as October, but only if vaccine production and testing run smoothly this summer.

GlaxoSmithKline taking pandemic vaccine orders

May 15, 2009

(AP) -- Pharmaceutical giant GlaxoSmithKline said Friday it has received orders from several countries to stockpile pandemic vaccine as soon as it gets the vaccine's key ingredient from the World Health Organization.

Bird flu vaccine not effective in trial

Feb 17, 2006

A highly anticipated bird flu vaccine trial in Australia has proven protective for only a small minority of the 400 volunteers in the clinical trial.

Recommended for you

Senegal monitors contacts of 1st Ebola patient

8 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

14 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

19 hours ago

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments : 0